Search Technologies
Displaying 41 - 50 of 84 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Use of ELA peptide for treatment of cardiovascular disease and for improving fluid homeostasis
Published Tuesday, October 20, 2015Cardiovascular disease (CVD) continues to be one of America’s most serious and costly health issues. Though many therapeutic options exist to treat CVD, the majority of treatments address the symptoms of the disease and not the disease itself. This technology is a new class of therapeutic fusion proteins using the hormone Elabela (ELA) to...
Investigator(s): Da-Wei Gong (Lead PI)
Categories: Therapeutics, Biologics, Methods of Treatment
Keyword(s): MI, peptide, heart failure, myocardial infarction, cardiovascular, obesity, ELA, apelin
Docket: DG-2014-128
-
Use of Micro-RNA Mimics as Therapeutic Agents for Inhibition of Neuronal Apoptosis Following Traumatic Brain Injury.
Published Tuesday, August 25, 2015Reduced blood flow to the brain due to thrombosis, embolism, cardiac arrest, or injury, can result in focal or global cerebral ischemia. Ischemia leads to alterations in brain metabolism, reduction in metabolic rates, and subsequent neuronal death. Ischemia can have irreversible sequela. Post-injury treatment to curtail cell death due to acute...
Investigator(s): Alan Faden, Bogdan Stoica, Boris Sabirzhanov
Categories: Therapeutics, Small molecules, Biologics
Keyword(s): Traumatic Brain Injury, micro RNA, miRNA mimics, ischemia
Docket: AF-2014-011
-
Protein-Coated Microspheres for the Treatment of Inflammatory Bowel Conditions
Published Tuesday, June 30, 2015Chronic inflammation of the bowel is estimated to affect over 20% of Americans with only a small subset of individuals being clinically diagnosed with the autoimmune diseases Crohn’s and ulcerative colitis (UC). Researchers at the University of Maryland, Baltimore have developed a targeted therapeutic approach that may be...
Investigator(s): Erik P.H. de Leeuw; Wuyuan Lu
Categories: Therapeutics, Biologics, Methods of Treatment
Keyword(s): microsphere, defensin, inflammatory bowel syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, surface-like protein
Docket: ED-2010-131
-
Tight junction permeation enhancer peptides
Published Monday, March 23, 2015Human zonulin or pre-haptoglobin 2 (HP2) is known to reversibly regulate intestinal permeability by modulating intercellular tight junctions. Itactivates protease-activated receptor (PAR) 2, and induces signaling...
Investigator(s): Alessio Fasano, Stefanie N. Vogel
Categories: Research Tools, Antibodies, & Reagents, Therapeutics, Small molecules, Biologics, Methods of Treatment
Keyword(s): peptides, zot, zonulin, crohns asthma, glioma, celiac disease, type I diabetes, tight junction
Docket: AF-2004-004
-
Use of Omentin for Treatment and Prediction of Disease
Published Wednesday, January 28, 2015Obesity, especially accumulation of abdominal fat, is a risk factor for the development of type 2 diabetes and cardiovascular disease. More than one-third of US adults are considered to be obese. Omentin is an adipokine expressed and secreted from abdominal but not subcutaneous...
Investigator(s): Da-Wei Gong, Alan Shuldiner, John McLenithan, Rongze Yang
Categories: Research Tools, Antibodies, & Reagents, Diagnostics, Therapeutics, Biologics, Biomaterials
Keyword(s): omentin, diabetes, obesity, cardiovascular
Docket: DG-2002-013, DG-2007-087, DG-2009-093
-
Repurposed drugs for Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Published Monday, November 24, 2014Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) are viral respiratory diseases caused by novel coronavirus strains (SARS-CoV and MERS-CoV, respectively). Categorized as a select agent in 2012, approximately 9,000 cases of SARS have been reported, with 9.5% mortality rate. To date, there have been 1,917...
Investigator(s): Mathew Frieman, Lisa Hensley, Peter Jahrling
Categories: Therapeutics, Small molecules, Chemicals, Repurpose Drug
Keyword(s): MERS, SARS, Repurposed drugs, antiviral drugs
Docket: MF-2014-090
-
Use of EM 1412 as a vaginal microbicide for HIV, HPV and HSV transmission
Published Friday, November 7, 2014Cervical dysplasia is the existence of abnormal cells in the cervix, which may indicate a pre-cancerous condition. In the United States, 250,000 to 1 million women are diagnosed with cervical dysplasia annually in which 30% to 50% possibly progressing to invasive cancer without treatment. In order to address this issue...
Investigator(s): Niharika Khanna, Neil Frazier, Ru Chi Huang
Categories: Therapeutics, Repurpose Drug, Natural Compounds
Docket: NK-2004-057
-
Vaccines Against ETEC with Isolation and Characterization of the csa Operon (ETEC-CS4 Pili)
Published Thursday, May 29, 2014Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in infants and young children in developing countries, accounting for a high rate of infantile morbidity and mortality, and is also a major cause of traveler's diarrhea. Following ingestion of contaminated food or water containing ETEC, the bacteria can attach to the small...
Investigator(s): Zeev Altboum, Myron Levine, Eileen Barry
Categories: Therapeutics, Vaccines
Keyword(s): vaccine, diarrheal
Docket: ZA-2000-053
-
Use of Trehalose for Prevention of Neural Tube Defects
Published Thursday, May 29, 2014The neural tube is a specialized part of the embryo that forms the skull, brain and spinal cord in adults and requires an effective balance between cell death and survival. Disruption of this process causes neural tube defects (NTDs) such as spina bifida, anencephaly, and encephalocele. UMB researchers have discovered Trehalose treatment...
Investigator(s): Peixin Yang, E. Albert Reece
Categories: Therapeutics, Small molecules
Keyword(s): Trehalose, diabetes
Docket: PY-2012-118
-
Use of Novel Sulfonamides to Inhibit the Growth of Prostate Cancer Cells and Tumors
Published Thursday, May 29, 2014According to the American Cancer Society, prostate cancer (PCA) is the most common type of cancer found in American men. Currently, the major therapy for PCA in both primary and advanced stages is androgen deprivation. This treatment exerts its effects on target tissue by either blocking androgen synthesis or preventing binding of androgens to...
Investigator(s): Vincent C. O. Njar, Puranik Purushottamachar
Categories: Therapeutics, Small molecules
Keyword(s): prostate cancer, cancer
Docket: VN-2007-026